{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:22:21Z","timestamp":1792092141913,"version":"4.4.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Melanoma is a highly aggressive and metastatic malignant tumor originating from melanocytes, with globally rising incidence rates that pose significant challenges to patient prognosis. Traditional therapies for advanced melanoma have limited efficacy. In recent years, the emergence of immune checkpoint inhibitors (ICIs) has significantly altered this landscape by reactivating the body\u2019s antitumor immune response through blocking interactions between immune checkpoint proteins and their ligands, demonstrating remarkable therapeutic outcomes. However, some patients do not respond to ICIs or develop resistance, indicating that treatment responses involve complex interactions between tumors, immune cells, and the tumor microenvironment. This review comprehensively summarizes the mechanisms of ICIs, delves into the roles of various immune cells (including T cells, NK cells, macrophages, T helper cells, dendritic cells, and B cells) and the tumor microenvironment (TME), and explores their impact on ICI efficacy. It further distinguishes the application of ICBs across different disease stages (primary, adjuvant, neoadjuvant, and metastatic) and highlights the role of skin-specific immune cells (e.g., TRM, Langerhans cells) and microenvironmental components (e.g., skin microbiome). This review focuses on the mechanisms of ICIs in melanoma therapy, exploring the interactions between immune cells and the skin microenvironment in melanoma development and their impact on ICI efficacy. It aims to provide new insights and theoretical foundations for optimizing immunotherapy strategies in melanoma treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1691608","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:40Z","timestamp":1763534140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment"],"prefix":"10.3389","volume":"16","author":[{"given":"Yiwen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113396","article-title":"Incidence of melanoma in Catalonia, Spain, is rapidly increasing in the elderly population. A multicentric cohort study","volume":"9","author":"Podlipnik","year":"2020","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3978\/j.issn.2305-5839.2015.12.23","article-title":"Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition)","volume":"3","author":"Guo","year":"2015","journal-title":"Ann Transl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-642-19022-3_8","article-title":"Chemosensitivity testing in Malignant melanoma","volume":"161","author":"Ugurel","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/pcmr.13037","article-title":"The delicate relation between melanocytes and skin immunity: A game of hide and seek","volume":"35","author":"Speeckaert","year":"2022","journal-title":"Pigment Cell Melanoma Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122430","article-title":"Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations","volume":"14","author":"Williams","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106770","DOI":"10.1016\/j.intimp.2020.106770","article-title":"Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens","volume":"87","author":"Yao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7150\/jca.32724","article-title":"Risk of immune-related diarrhea with PD-1\/PD-L1 inhibitors in different cancer types and treatment regimens","volume":"11","author":"Zhao","year":"2020","journal-title":"J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211056","article-title":"Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K\/Akt pathway","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: new insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1816342","article-title":"Keratinocyte autophagy enables the activation of keratinocytes and fibroblastsand facilitates wound healing","volume":"17","author":"Qiang","year":"2021","journal-title":"Autophagy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.11.011","article-title":"Self-assembly of mesoscale collagen architectures and applications in 3D cell migration","volume":"155","author":"Liu","year":"2023","journal-title":"Acta Biomater"},{"key":"B12","doi-asserted-by":"publisher","first-page":"151447","DOI":"10.1016\/j.ejcb.2024.151447","article-title":"Mechanisms of lymph node metastasis: An extracellular vesicle perspective","volume":"103","author":"Garc\u00eda-Silva","year":"2024","journal-title":"Eur J Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000007800","article-title":"Analysis of clinical characteristics and prognosis of patients with periocular Malignant melanoma in Korea","volume":"32","author":"Park","year":"2021","journal-title":"J Craniofac Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0980","article-title":"MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: A retrospective study of 2,793 cases","volume":"23","author":"Bai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-009-0762-6","article-title":"Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites","volume":"454","author":"Sekine","year":"2009","journal-title":"Virchows Arch"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jop.12358","article-title":"Mutation scanning of BRAF, NRAS, KIT, and GNAQ\/GNA11 in oral mucosal melanoma: a study of 57 cases","volume":"45","author":"Lyu","year":"2016","journal-title":"J Oral Pathol Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1477-7819-11-291","article-title":"The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors","volume":"11","author":"Choi","year":"2013","journal-title":"World J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153319","article-title":"BRAF V600E and TERT promoter mutations in papillary thyroid carcinoma in chinese patients","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":"Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01315-x","article-title":"In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer","volume":"23","author":"Dubrot","year":"2022","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13277-015-4315-0","article-title":"Regulatory T cells in the immunotherapy of melanoma","volume":"37","author":"Ouyang","year":"2016","journal-title":"Tumour Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.38","article-title":"Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells","volume":"91","author":"Harimoto","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.746","article-title":"Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma","volume":"10","author":"Li","year":"2022","journal-title":"Immun Inflammation Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1591-2","article-title":"Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer","volume":"63","author":"Idorn","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2023_90-215","article-title":"Immune checkpoint inhibitors and associated pituitary dysfunctions: A mini-review","volume":"90","author":"Fukuda","year":"2023","journal-title":"J Nippon Med Sch"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02538-4","article-title":"Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma","volume":"474","author":"Ottaviano","year":"2019","journal-title":"Virchows Arch"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S148009","article-title":"Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer","volume":"10","author":"Shafique","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13730","article-title":"Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma","volume":"17","author":"Hu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S78039","article-title":"Clinical utility of nivolumab in the treatment of advanced melanoma","volume":"12","author":"Asmar","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2984-9","article-title":"T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands","volume":"145","author":"Karasar","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J Transl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-024-00515-5","article-title":"Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1\/PD-L1 and regulatory pathways","volume":"13","author":"Wang","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155778","article-title":"Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy","volume":"14","author":"Farhangnia","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-022-2556-x","article-title":"Anti-hepatoma effect of DC2.4 cells transfected with tumor-associated antigen cdc25C in vitro","volume":"42","author":"Li","year":"2022","journal-title":"Curr Med Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.clbc.2022.12.020","article-title":"Immunomodulatory role of diospyros peregrina fruit preparation in breast cancer by utilizing macrophage mediated antigen presentation and T helper cell (Th) differentiation","volume":"23","author":"Mahalakshmi Surendran","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-017-0403-5","article-title":"PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40820-021-00622-6","article-title":"Recent advancements in nanomedicine for 'Cold' Tumor immunotherapy","volume":"13","author":"Chen","year":"2021","journal-title":"Nanomicro Lett"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/intimm\/dxad035","article-title":"Metabolic advantages of regulatory T cells dictated by cancer cells","volume":"36","author":"Kondo","year":"2024","journal-title":"Int Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006345","article-title":"ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers","volume":"11","author":"Yu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1714","article-title":"PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses","volume":"36","author":"Medina","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-021-01492-7","article-title":"Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy","volume":"21","author":"Hosseini","year":"2022","journal-title":"Mol Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8397","article-title":"PILR\u03b1 binds an unknown receptor expressed primarily on CD56bright and decidual-NK cells and activates NK cell functions","volume":"7","author":"Ophir","year":"2016","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136741","article-title":"MHC class I deficiency in solid tumors and therapeutic strategies to overcome it","volume":"22","author":"Shklovskaya","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/j.seminhematol.2020.10.002","article-title":"Natural killer cell engineering - a new hope for cancer immunotherapy","volume":"57","author":"Lin","year":"2020","journal-title":"Semin Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00335","article-title":"Human NK cell lytic granules and regulation of their exocytosis","volume":"3","author":"Krzewski","year":"2012","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1039260","article-title":"The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy","volume":"13","author":"Lu","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02808.x","article-title":"Regulatory allospecific NK cell function is differentially associated with HLA C allotypes","volume":"9","author":"Zenhaeusern","year":"2009","journal-title":"Am J Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-021-00648-w","article-title":"Targeting of the tumor immune microenvironment by metformin","volume":"16","author":"Wu","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0444-2","article-title":"IL-2 and IL-15 induced NKG2D, CD158a and CD158b expression on T, NKT- like and NK cell lymphocyte subsets from regional lymph nodes of melanoma patients","volume":"26","author":"Vuleti\u0107","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189975","article-title":"Ex vivo expanded and activated natural killer cells prolong the overall survival of mice with glioblastoma-like cell-derived tumors","volume":"22","author":"Shida","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2015-0012OC","article-title":"Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages","volume":"53","author":"Tarique","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03726-13","article-title":"Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination","volume":"88","author":"Byrd","year":"2014","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-023-00992-6","article-title":"Targeting circulating tumor cells to prevent metastases","volume":"37","author":"Gostomczyk","year":"2024","journal-title":"Hum Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"117064","DOI":"10.1016\/j.biopha.2024.117064","article-title":"Engineering M1 macrophages with targeting aptamers for enhanced adoptive immunotherapy by modifying the cell surface","volume":"177","author":"Yang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1382256","article-title":"Tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-022-05077-3","article-title":"Melanoma-associated macrophages-from molecular signals to therapeutic application","volume":"73","author":"Chatziioannou","year":"2022","journal-title":"Dermatologie (Heidelb)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"119418","DOI":"10.1016\/j.carbpol.2022.119418","article-title":"In situ injectable nano-complexed hydrogel based on chitosan\/dextran for combining tumor therapy via hypoxia alleviation and TAMs polarity regulation","volume":"288","author":"Zhang","year":"2022","journal-title":"Carbohydr Polym"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","article-title":"Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies","volume":"10","author":"Zhu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-022-01377-2","article-title":"Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study","volume":"15","author":"Spalato-Ceruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"B68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006896","article-title":"CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1969767","DOI":"10.1080\/2162402X.2021.1969767","article-title":"Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas","volume":"10","author":"Jia","year":"2021","journal-title":"Oncoimmunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.1038\/s41598-022-14319-2","article-title":"Integrated analysis reveals the pivotal interactions between immune cells in the melanoma tumor microenvironment","volume":"12","author":"Chen","year":"2022","journal-title":"Sci Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02793-5","article-title":"Microenvironmental Snail1-induced immunosuppression promotes melanoma growth","volume":"42","author":"Arumi-Planas","year":"2023","journal-title":"Oncogene"},{"key":"B74","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","article-title":"Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163906","article-title":"Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy","volume":"14","author":"Glabman","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105283","article-title":"Influence of tumor microenvironment and fibroblast population plasticity on melanoma growth, therapy resistance and immunoescape","volume":"22","author":"Romano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2008.00450.x","article-title":"Transforming growth factor-beta in cutaneous melanoma","volume":"21","author":"Javelaud","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20245","article-title":"Genetic variants of PDGF signaling pathway genes predict cutaneous melanoma survival","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4174\/astr.2015.89.1.1","article-title":"Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis","volume":"89","author":"Lee","year":"2015","journal-title":"Ann Surg Treat Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700167","article-title":"Cancer associated fibroblasts: the architects of stroma remodeling","volume":"18","author":"Santi","year":"2018","journal-title":"Proteomics"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174216","article-title":"Melanoma tumour vascularization and tissue-resident endothelial progenitor cells","volume":"14","author":"Hashemi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.14670\/HH-20.155","article-title":"Characteristics of lymphatic endothelial cells in physiological and pathological conditions","volume":"20","author":"Ji","year":"2005","journal-title":"Histol Histopathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00621","article-title":"The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment","volume":"7","author":"Hendry","year":"2016","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004771","article-title":"Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy","volume":"10","author":"Attrill","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4103\/0973-029X.99077","article-title":"Pathophysiology of langerhans cells","volume":"16","author":"Jaitley","year":"2012","journal-title":"J Oral Maxillofac Pathol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl024","article-title":"Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis","volume":"18","author":"Bennaceur","year":"2006","journal-title":"Int Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142067","article-title":"Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin","volume":"5","author":"Jiang","year":"2020","journal-title":"JCI Insight"},{"key":"B88","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.imlet.2019.03.011","article-title":"Mast cells: A double-edged sword in cancer","volume":"209","author":"Derakhshani","year":"2019","journal-title":"Immunol Lett"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911789","article-title":"Hypoxia-regulated tumor-derived exosomes and tumor progression: A focus on immune evasion","volume":"23","author":"Shao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082145","article-title":"Modeling extracellular matrix-cell interactions in lung repair and chronic disease","volume":"10","author":"Hackett","year":"2021","journal-title":"Cells"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2005001000005","article-title":"Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix","volume":"38","author":"Paez-Pereda","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924553","article-title":"Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance","volume":"12","author":"Popovic","year":"2022","journal-title":"Front Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1535-7163.MCT-22-0595","article-title":"Interplay between extracellular matrix remodeling and angiogenesis in tumor ecosystem","volume":"22","author":"Siddhartha","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-017-1392-0","article-title":"Acquisition of anoikis resistance promotes alterations in the Ras\/ERK and PI3K\/Akt signaling pathways and matrix remodeling in endothelial cells","volume":"22","author":"de Sousa Mesquita","year":"2017","journal-title":"Apoptosis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112759","article-title":"ECM remodeling in squamous cell carcinoma of the aerodigestive tract: pathways for cancer dissemination and emerging biomarkers","volume":"13","author":"Fejza","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.358","article-title":"Interplay between cadherins and \u03b12\u03b21 integrin differentially regulates melanoma cell invasion","volume":"113","author":"Siret","year":"2015","journal-title":"Br J Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13046-022-02484-1","article-title":"The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes","volume":"41","author":"Jurj","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1270981","article-title":"The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature","volume":"14","author":"Fejza","year":"2023","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2016.1221566","article-title":"Fibronectin induces macrophage migration through a SFK-FAK\/CSF-1R pathway","volume":"11","author":"Digiacomo","year":"2017","journal-title":"Cell Adh Migr"},{"key":"B100","doi-asserted-by":"publisher","first-page":"11164","DOI":"10.1038\/s41598-020-67430-7","article-title":"A novel humanized mouse model to study the function of human cutaneous memory T cells in vivo in human skin","volume":"10","author":"Klicznik","year":"2020","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2010.00959.x","article-title":"Intracellular cytokine production in peripheral blood lymphocytes: a comparison of values in infertile and fertile women","volume":"65","author":"Hork\u00e1","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092508","article-title":"Insights into differentiation of melanocytes from human stem cells and their relevance for melanoma treatment","volume":"12","author":"Mirea","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cyto.2014.10.031","article-title":"Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy","volume":"74","author":"Saxena","year":"2015","journal-title":"Cytokine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1038\/s41467-021-22923-5","article-title":"A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages","volume":"12","author":"Huffaker","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"216265","DOI":"10.1016\/j.canlet.2023.216265","article-title":"CDYL knockdown reduces glioma development through an antitumor immune response in the tumor microenvironment","volume":"567","author":"Kong","year":"2023","journal-title":"Cancer Lett"},{"key":"B108","doi-asserted-by":"publisher","first-page":"156629","DOI":"10.1016\/j.cyto.2024.156629","article-title":"Is it possible to treat melanoma by intercepting the CXCR4\/CXCL12 pathway","volume":"179","author":"Motlak","year":"2024","journal-title":"Cytokine"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.670976","article-title":"PAX3 and FOXD3 promote CXCR4 expression in melanoma","volume":"290","author":"Kubic","year":"2015","journal-title":"J Biol Chem"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 axis in tumor immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr Med Chem"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00835","article-title":"Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients","volume":"9","author":"Kim","year":"2019","journal-title":"Front Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011706","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial","volume":"13","author":"Block","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"178","DOI":"10.31083\/j.fbl2905178","article-title":"Research progress of warburg effect in hepatocellular carcinoma","volume":"29","author":"Yang","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12444","article-title":"The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells","volume":"280","author":"Moreno","year":"2013","journal-title":"FEBS J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32984","article-title":"Outcomes after progression of disease with anti-PD-1\/PD-L1 therapy for patients with advanced melanoma","volume":"126","author":"Patrinely","year":"2020","journal-title":"Cancer"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207544","article-title":"Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255716","article-title":"Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis","volume":"16","author":"Mineiro Dos Santos Garrett","year":"2021","journal-title":"PLoS One"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: A systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296626","article-title":"Determination of elevated eosinophil to lymphocyte ratio, eosinophil to neutrophil ratio, eosinophil to monocyte ratio and its association with severe vitiligo: A retrospective cohort study","volume":"19","author":"Weissmann","year":"2024","journal-title":"PLoS One"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012070","article-title":"A correlation between gastrointestinal dysfunction and cirrhosis severity","volume":"97","author":"Wang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15041","article-title":"Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan","volume":"35","author":"Kitagataya","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-020-02209-y","article-title":"Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts","volume":"18","year":"2020","journal-title":"J Transl Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf268","article-title":"Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III\/IV melanoma: A nationwide real-life study in France (NEOMEL)","volume":"7","author":"Nardin","year":"2025","journal-title":"Br J Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000736","article-title":"Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors","volume":"31","author":"Holstead","year":"2021","journal-title":"Melanoma Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133186","article-title":"Clinical and molecular heterogeneity in patients with innate resistance to anti-PD-1 +\/- anti-CTLA-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets","volume":"13","author":"Gide","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-230039","article-title":"Immune checkpoint inhibitors in metastatic bladder and other solid Malignancies: how long is enough","volume":"9","author":"Kumar","year":"2023","journal-title":"Bladder Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205134","article-title":"Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma","volume":"13","author":"Garc\u00eda-Sancha","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B142","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00262-024-03825-z","article-title":"Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors","volume":"73","author":"Malhotra","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B143","doi-asserted-by":"publisher","first-page":"89","DOI":"10.21037\/tgh.2018.10.16","article-title":"Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment","volume":"3","author":"Siu","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691608\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:35:45Z","timestamp":1763534145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1691608\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":144,"alternative-id":["10.3389\/fimmu.2025.1691608"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1691608","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1691608"}}